Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up

MLA

Rachel Slottke, et al. “Pembrolizumab (Pembro) plus Enzalutamide (Enz) in Metastatic Castration Resistant Prostate Cancer (MCRPC): Extended Follow Up.” Journal of Clinical Oncology, vol. 36, May 2018, p. 5047. EBSCOhost, https://doi.org/10.1200/jco.2018.36.15_suppl.5047.

APA

Rachel Slottke, Tomasz M. Beer, Charles G. Drake, Joshi J. Alumkal, Mary A. Wood, George Thomas, Amy E. Moran, Julie N. Graff, & Reid F. Thompson. (2018). Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up. Journal of Clinical Oncology, 36, 5047. https://doi.org/10.1200/jco.2018.36.15_suppl.5047

Chicago

Rachel Slottke, Tomasz M. Beer, Charles G. Drake, Joshi J. Alumkal, Mary A. Wood, George Thomas, Amy E. Moran, Julie N. Graff, and Reid F. Thompson. 2018. “Pembrolizumab (Pembro) plus Enzalutamide (Enz) in Metastatic Castration Resistant Prostate Cancer (MCRPC): Extended Follow Up.” Journal of Clinical Oncology 36 (May): 5047. doi:10.1200/jco.2018.36.15_suppl.5047.